Pathogenesis, natural history, treatment, and prevention of hepatitis C

Annals of Internal Medicine

Volumn 132, Issue 4, 2000, Pages 296-305

  Liang, T Jake ^a   Rehermann, Barbara ^a   Seeff, Leonard B ^a   Hoofnagle, Jay H ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS C VACCINE; INTERFERON; RIBAVIRIN;

ANEMIA; CELLULAR IMMUNITY; CONFERENCE PAPER; DISEASE COURSE; HEMOLYSIS; HEPATITIS C; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; PERSISTENT INFECTION; PRIORITY JOURNAL; TREATMENT PLANNING; UNITED STATES; VIRUS GENOME;

EID: 0034651580     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-132-4-200002150-00008     Document Type: Conference Paper

References (77)

1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989;88:359-62.
2. Major ME, Feinstone SM. The molecular virology of hepatitis C. Hepatology. 1997;25:1527-38.
3. Alter MJ. Epidemiology of hepatitis C. Hepatology. 1997;26:62S-5S.
4. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, et al. Binding of hepatitis C virus to CD81. Science. 1998;282:938-41.
5. Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper ard a T-killer cell. Nature. 1998; 393:474-8.
6. Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV. Viral clearance without destruction of infected cells during acute HBV infection. Science. 1999;284:825-9.
7. Pavic I, Polic B, Crnkovic I, Lucin P, Jonjic S, Koszinowski UH. Participation of endogenous tumour necrosis factor alpha in host resistance to cytomegalovirus infection. J Gen Virol. 1993;74:2215-23.
8. Franco MA, Tin C, Rott LS, VanCott JL, McGhee JR, Greenberg HB. Evidence for CDS+ T-cell immunity to murine rotavirus in the absence of perforin, fas, and gamma interferon. J Virol. 1997;71:479-86.
9. Kurosaki M, Enomoto N, Marumo F, Sato C. Rapid sequence variation of the hypervariable region of hepatitis C virus during the course of chronic infection. Hepatology. 1993;18:1293-9.
10. Weiner AJ, Brauer MJ, Rosenblatt J, Richman KH, Tung J, Crawford K, et al. Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology. 1991;180:842-8.
11. Kato N, Sekiya H, Ootsuyama Y, Nakazawa T, Hijikata M, Ohkoshi S, et al. Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus. J Virol. 1993;67:3923-30.
12. Farci P, Shimoda A, Wong D, Cabezon T, De Gioannis D, Strazzera A, et al. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci U S A. 1996;93:15394-9.
13. Weiner AJ, Geysen HM, Christopherson C, Hall JE, Mason T, Saracco G, et al. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. Proc Natl Acad Sci U S A. 1992;89:3468-72.
14. Farci P, Alter HJ, Govindarajan S, Wong DC, Engle R, Lesniewski RR, et al. Lack of protective immunity against reinfection with hepatitis C virus. Science. 1992;258:135-40.
15. Bassett SE, Thomas DL, Brasky KM, Lanford RE. Viral persistence, antibody to E1 and E2, and hypervariable region 1 sequence stability in hepatitis C virus-inoculated chimpanzees J Virol, 1999;73:1118-26.
16. Major ME, Mihalik K, Fernandez J, Seidman J, Kleiner D, Kolykhalov AA, et al. Long-term follow-up of chimpanzees inoculated with the first infectious clone for hepatitis C virus. J Virol. 1999;73:3317-25.
17. Diepolder HM, Gerlach JT, Zachoval R, Hoffmann RM, Jung MC, Wierenga EA, et al. Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J Virol. 1997;71: 6011-9.
18. Missale G, Bertoni R, Lamonaca V, Valli A, Massari M, Mori C, et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest. 1995;98:706-14.
19. Chang KM, Gruener NH, Southwood S, Sidney J, Pape GR, Chisari FV, et al. Identification of HLA-A3 and -B7-restricted CTL response to hepatitis C virus in patients with acute and chronic hepatitis C. J Immunol. 1999;162: 1156-64.
20. Lamonaca V, Missale G, Urbani S, Pilli M, Boni C, Mori C, et al. Conserved hepatitis C virus sequences are highly immunogenic for CD4(+) T cells: implications for vaccine development. Hepatology. 1999;30:1088-98.
21. Cooper S, Erickson AL, Adams EJ, Kansopon J, Weiner AJ, Chien DY, et al. Analysis of a successful immune response against hepatitis C virus. Immunity. 1999;10:439-49.
22. Rehermann B, Chang KM, McHutchison JG, Kokka R, Houghton M, Chisari FV. Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection. J Clin Invest. 1996;98:1432-40.
23. Borysiewicz LK, Morris S, Page JD, Sissons JG. Human cytomegalovirus-specific cytotoxic T lymphocytes: requirements for in vitro generation and specificity. Eur J Immunol. 1983;13:804-9.
24. Weiner A, Erickson AL, Kansopon J, Crawford K, Muchmore E, Hughes AL, et al. Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant. Proc Natl Acad Sci U S A. 1995;92:2755-9.
25. Chang KM, Rehermann B, McHutchison JG, Pasquinelli C, Southwood S, Sette A, et al. Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus. J Clin Invest. 1997;100:2376-85.
26. Kaneko T, Moriyama T, Udaka K, Hiroishi K, Kita H, Okamoto H, et al. Impaired induction of cytotoxic T lymphocytes by antagonism of a weak agonist borne by a variant hepatitis C virus epitope. Eur J Immunol. 1997;27: 1782-7.
27. Large MK, Kittlesen DJ, Hahn YS. Suppression of host immune response by the core protein of hepatitis C virus: possible implications for hepatitis C virus persistence. J Immunol. 1999;162:931-8.
28. Taylor DR, Shi ST, Romano PR, Barber GN, Lai MM. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science. 1999; 285:107-10.
29. Gale M Jr, Kwleciszewski B, Dossett M, Nakao H, Katze MG. Anti-apoptotic and oncogenic potentials of hepatitis C virus are linked to interferon resistance by viral repression of the PKR protein kinase. J Virol. 1999; 73:6506-16.
30. Nuti S, Rosa D, Valiante NM, Saletti G, Caratozzolo M, Dellabona P, et al. Dynamics of intra-hepatic lymphocytes in chronic hepatitis C: enrichment for Valpha24+ T cells and rapid elimination of effector cells by apoptosis. Eur J Immunol. 1998;28:3448-55.
31. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349:825-32.
32. Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ. Long-term clinical and histopathological follow-up of chronic post-transfusion hepatitis. Hepatology. 1991;14:969-74.
33. Hopf U, Moller B, Kuther D, Stemerowicz R, Lobeck H, Ludtke-Handjery A, et al. Long-term follow-up of posttransfusion and sporadic chronic hepatitis non-A, non-B and frequency of circulating antibodies to hepatitis C virus (HCV). J Hepatol. 1990;10:69-76.
34. Koretz RL, Abbey H, Coleman E, Gitnick G. Non-A, non-B post-transfusion hepatitis. Looking back in the second decade. Ann Intern Med. 1993; 119:110-5.
35. Mattsson L, Sonnerborg A, Weiland O. Outcome of acute symptomatic non-A, non-B hepatitis: a 13-year follow-up study of hepatitis C virus markers. Liver. 1993;13:274-8.
36. Tremolada F, Casarin C, Alberti A, Drago C, Tagger A, Ribero ML, et al. Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. J Hepatol. 1992;16:273-81.
37. Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology. 1996;23:1334-40.
38. Takahashi M, Yamada G, Miyamoto R, Doi T, Endo H, Tsuji T. Natural course of chronic hepatitis C. Am J Gastroenterol. 1993;88:240-3.
39. Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med. 1995;332:1463-6.
40. Kenny-Walsh E. Clinical outcomes after hepatitis C nfection from contaminated anti-D immune globulin. N Engl J Med. 1999;340:1228-33.
41. Seeff LB, Buskell-Bales Z, Wright EC, Durako SJ, Alter HJ, Iber FL, et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis The National Heart, Lung, and Blood Institute Study Group. N Engl J Med. 1992; 327:1906-11.
42. Wright E, Seeff L, Hollinger F, Alter H, Buskell-Bales Z, Cain C, et al. Updated long-term morbidity of transfusion-associated hepatitis (TAH), non-A, non-B and C [Abstract]. Hepatology. 1998;28:A272.
43. Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, Hurter D, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology. 1998;28:1687-95.
44. Seeff LB, Miller RN, Rabkin CS, Buskell-Bales Z, Smoak B, Straley-Eason KD, et al. 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med. 2000;132:105-11.
45. National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C Hepatology. 1997;26:25-105.
46. Bodenheimer HC Jr, Lindsay KL, Davis GL, Lewis JH, Thung SN, Seeff LB. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial Hepatology. 1997;26:473-7.
47. Di Bisceglie AM, Conjeevaram HS, Fried MW, Sallie R, Park Y, Yurdaydin C, et al. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995;123:897-903.
48. Dusheiko G, Main J, Thomas H, Reichard O, Lee C, Dhillon A, et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol. 1996;25:591-8.
49. McHutchison JG, Gordon SC, Schiff ER, Shiftman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group N Engl J Med. 1998;339:1485-92.
50. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, et al. Interferon alpha-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med. 1998;339:1493-9.
51. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group. Lancet. 1998;352:1426-32.
52. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology. 1996;24:778-89.
53. Lau DT, Kleiner DE, Ghany MG, Park Y, Schmid P, Hoofnagle JH. 10-year follow-up after interferon-alpha therapy for chronic hepatitis C. Hepatology. 1998;28:1121-7.
54. Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med. 1997;127:875-81.
55. Schvara R, Yun ZB, Sonnerborg A, Weiland O. Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone. J Med Virol. 1995;46:43-7.
56. Heathcote EJ, Keeffe EB, Lee SS, Feinman SV, Tong MJ, Reddy KR, et al. Re-treatment of chronic hepatitis C with consensus interferon. Hepatology. 1998;27:1136-43.
57. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science. 1998;282:103-7.
58. Hu ZX, Hoffman J, Patel I, Joubert P. Single-dose, safety-tolerability and pharmacokinetic-pharmacodynamics following administration of ascending subcutaneous doses of pegylated-interferon and interferon alpha-2a to healthy subjects [Abstract]. Hepatology. 1998;28:A708.
59. Shiffman M, Hofmann C, Sanyal A, Luketic V, Sterling R, Ferreira-Gonzalez A, et al. The effect of maintenance interferon in chronic HCV non-responders: results of a randomized controlled trial [Abstract]. Gastroenterology. 1998;114:A9.
60. Hoofnagle JH, Lau D, Conjeevaram H, Kleiner D, Di Bisteglie AM. Prolonged therapy of chronic hepatitis C with ribavirin. J Viral Hepat. 1996; 3:247-52.
61. Fattovich G, Giustina G, Degos F, Diodati G, Tremolada F, Nevens F, et al. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol. 1997;27:201-5.
62. Imai Y, Kawata S, Tamura S, Yabuuchi I, Noda S, Inada M, et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocelluar Carcinoma Prevention Study Group. Ann Intern Med. 1998;129:94-9.
63. Nishiguthi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, et al. Randomised trial of effects of interferon alfa on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet. 1995; 346:1051-5.
64. Shimizu YK, Hijikata M, Iwamoto A, Alter HJ, Purcell RH, Yoshikura H. Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses. J Virol. 1994;68 1494-500.
65. Chen M, Sallberg M, Sonnerborg A, Weiland O, Mattsson L, Jin L, et al. Limited humoral immunity in hepatitis C virus infection. Gastroenterology. 1999;116:135-43.
66. Bassett SE, Brasky KM, Lanford RE. Analysis of hepatitis C virus-inoculated chimpanzees reveals unexpected clinical profiles. J Virol. 1998;72:2589-99.
67. Prince AM, Brotman B, Huima T, Pascual D, Jaffery M, Inchauspe G. Immunity in hepatitis C infection. J Infect Dis. 1992;165:438-43.
68. Alter HJ, Conry-Cantilena C, Melpolder J, Tan D, Van Raden M, Herion D, et al. Hepatitis C in asymptomatic blood donors. Hepatology 1997;26: 29S-33S.
69. Tsai SL, Liaw YF, Chen MH, Huang CY, Kuo GC. Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. Hepatology. 1997;25:449-58.
70. Choo QL, Kuo G, Ralston R, Weiner AJ, Chien D, Van Nest G, et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci U S A. 1994;91:1294-8.
71. Koziel MJ, Liang TJ. Vaccination against hepatitis C virus infection: miles to go before we sleep [Editorial]. Hepatology. 1994;20:758-60.
72. Koziel M, Liang TJ. DNA vaccines and viral hepatitis: are we going around in circles? Gastroenterology. 1997;112:1410-4.
73. Varnavski AN, Khromykh AA. Norcytopathic flavivirus replicon RNA-based system for expression and delivery of heterologous genes Virology. 1999; 255:366-75.
74. Baumert TF, Vergalla J, Satoi J, Thomson M, Lechman M. Herion D, et al. Hepatitis C viruslike particles synthesized in insect cells as a potential vaccine candidate. Gastroenterology. 1999;117:1397-407.
75. Tobin GJ, Li GH, Fong SE, Nagashima K, Gonda MA. Chimeric HIV-1 virus-like particles containing gp120 epitopes as a result of a ribosomal frame-shift elicit Gag- and SU-specific murine cytotoxic T-lymphocyte activities. Virology. 1997;236:307-15.
76. Schirmbeck R, Melber K, Kuhroeber A, Janowicz ZA, Reimann J. Immunization with soluble hepatitis B virus surface protein elicits murine H-2 class I-restricted CD8+ cytotoxic lymphocyte responses in vivo. J Immunol. 1994;152:1110-9.
77. Greenstone HL, Nieland JD, de Visser KE, De Bruijn ML, Kirnbauer R, Roden RB, et al. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc Natl Acad Sci U S A. 1998;95:1800-5